Literature DB >> 24076262

Advances in the development of Rho-associated protein kinase (ROCK) inhibitors.

Peichen Pan1, Mingyun Shen, Huidong Yu, Youyong Li, Dan Li, Tingjun Hou.   

Abstract

Rho-associated protein kinases (ROCK1 and ROCK2) belong to the AGC family of serine-threonine kinases, and regulate a wide range of fundamental cell functions. Inhibition of ROCK has been proven to be of potential therapeutic benefit for a variety of diseases. In this review, the structures and therapeutic importance of ROCK are discussed briefly. Then, the recent status of the development of ROCK inhibitors is also summarized. Our review offers a foundation outline from which strategies to design new leads against ROCK can be developed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24076262     DOI： 10.1016/j.drudis.2013.09.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  22 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  L-F001, a Multifunction ROCK Inhibitor Prevents 6-OHDA Induced Cell Death Through Activating Akt/GSK-3beta and Nrf2/HO-1 Signaling Pathway in PC12 Cells and Attenuates MPTP-Induced Dopamine Neuron Toxicity in Mice.

Authors:  Liting Luo; Jingkao Chen; Dan Su; Meihui Chen; Bingling Luo; Rongbiao Pi; Lan Wang; Wei Shen; Rikang Wang
Journal:  Neurochem Res       Date:  2017-01-11       Impact factor: 3.996

3.  Partial contribution of Rho-kinase inhibition to the bioactivity of Ganoderma lingzhi and its isolated compounds: insights on discovery of natural Rho-kinase inhibitors.

Authors:  Yhiya Amen; Qinchang Zhu; Hai-Bang Tran; Mohamed S Afifi; Ahmed F Halim; Ahmed Ashour; Kuniyoshi Shimizu
Journal:  J Nat Med       Date:  2017-01-10       Impact factor: 2.343

4.  In silico prediction of ROCK II inhibitors by different classification approaches.

Authors:  Chuipu Cai; Qihui Wu; Yunxia Luo; Huili Ma; Jiangang Shen; Yongbin Zhang; Lei Yang; Yunbo Chen; Zehuai Wen; Qi Wang
Journal:  Mol Divers       Date:  2017-08-02       Impact factor: 2.943

5.  Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.

Authors:  Cristina Rozo; Yurii Chinenov; Reena Khianey Maharaj; Sanjay Gupta; Laura Leuenberger; Kyriakos A Kirou; Vivian P Bykerk; Susan M Goodman; Jane E Salmon; Alessandra B Pernis
Journal:  Ann Rheum Dis       Date:  2016-11-09       Impact factor: 19.103

6.  Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism.

Authors:  T Michael De Silva; Pimonrat Ketsawatsomkron; Christopher Pelham; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2014-11-10       Impact factor: 10.190

Review 7.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

8.  Human airway musculature on a chip: an in vitro model of allergic asthmatic bronchoconstriction and bronchodilation.

Authors:  Alexander Peyton Nesmith; Ashutosh Agarwal; Megan Laura McCain; Kevin Kit Parker
Journal:  Lab Chip       Date:  2014-10-21       Impact factor: 6.799

9.  A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion.

Authors:  Vijay Pralhad Kale; Jeremy A Hengst; Dhimant H Desai; Taryn E Dick; Katherine N Choe; Ashley L Colledge; Yoshinori Takahashi; Shen-Shu Sung; Shantu G Amin; Jong K Yun
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

Review 10.  Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases.

Authors:  Robert N Mahon; Richard Hafner
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.